Maravai LifeSciences (MRVI) Social Stream

Featured Post From StockTwits About MRVI

$MRVI Q2 Earnings beat on Tuesday. Raised guidance. With post-earnings upgrades, the stock is now up 46% since mid-July. Would wait for a pullback here to add.

•Q2 Revenue $217.8M vs consensus estimate of $192.29M.
•Sees FY21 revenue $745M-$770M, consensus $709.65M.
•Sees FY21 EPS $1.30-$1.36, consensus $1.15

CEO: "We anticipate continued robust growth in our Nucleic Acid Production business, and we are increasing our guidance to reflect stronger demand expectations for the remainder of the year."

Analyst upgrades:
$62 Morgan Stanley
$59 Baird
$58 KeyBanc
$57 BofA
$56 Stifel
$54 Credit Suisse